... to hormone-sensitive PCa patients. Conclusions: AAT alters TRAIL death ligand and its receptors expression in patients with PCa. 5 08 2009 20 10 2009 26 3 2010 Prostate cancer TRAIL Androgen ablation therapy Hormone-refractory prostate cancer Urologia Internationalis Original...

...Hai Liang Zhang; Ding Wei Ye; Xu Dong Yao; Bo Dai; Shi Lin Zhang; Yi Jun Shen; Yao Zhu; Wen Zhang Purpose: To preliminarily investigate the efficacy of docetaxel plus prednisone and mitoxantrone plus prednisone for treating metastatic hormone-refractory prostate cancer and to further evaluate its...

... cytotoxic agents has been widely used in clinical trials as an anti-tumor agent for the treatment of hormone-refractory prostate cancer (HRPC). However, few prospective studies have considered the efficacy of EMP monotherapy for HRPC patients following androgen-deprivation therapy (ADT), given...

...Masaaki Morioka; Tatsuya Kobayashi; Yoji Furukawa; Yoshimasa Jo; Masanori Shinkai; Takakazu Matsuki; Tokunori Yamamoto; Hiroyoshi Tanaka Objective: The efficacy of low-dose dexamethasone (DXM) therapy in patients with hormone-refractory prostate cancer (HRPC) was evaluated. Patients and Methods...

... decline following oral endocrine withdrawal may maintain hormonal sensitivity. Hormone-refractory prostate cancer Hormonal sensitivity Prostate-specific antigen Dexamethasone Original Paper Urol Int 2000;65:28 31 Received: February 7, 2000 Accepted: April 6, 2000 Hormonal Sensitivity following...